Keysser M
Rheumatologische Abteilung, Klinik für Innere Medizin des Klinikums Rostock-Südstadt.
Z Rheumatol. 1993 May-Jun;52(3):133-7.
In an open study 528 patients affected with rheumatoid-arthritis were treated with azathioprine, then observed for a period of at least 4 years and assessed according to Steinbrocker's therapeutic criteria. In 178 of them (33.7%) the therapy was still effective even after that time, which corresponds to grade I and II according to Steinbrocker. The therapy was cancelled in 211 patients due to ineffectiveness and in 85 patients due to side-effects. The side-effects are represented in detail. Owing to the favorable relationship between benefit and risk, azathioprine proves to be a means of first choice in all cases with a high process activity and an unfavorable prognosis.
在一项开放性研究中,528例类风湿性关节炎患者接受硫唑嘌呤治疗,随后观察至少4年,并根据斯坦布鲁克治疗标准进行评估。其中178例(33.7%)即使在该时间段后治疗仍有效,根据斯坦布鲁克标准相当于I级和II级。211例患者因治疗无效而停止治疗,85例患者因副作用而停止治疗。详细列出了副作用情况。由于获益与风险之间的良好关系,硫唑嘌呤被证明是所有疾病活动度高且预后不良病例的首选治疗手段。